참고문헌
- Dhar Chowdhury S, Oommen AM. Epidemiology of COVID-19. J Dig Endosc 2020;11:3-7. https://doi.org/10.1055/s-0040-1712187
- Pokhrel S, Chhetri R. A literature review on impact of COVID-19 pandemic on teaching and learning. High Educ Future 2021;8:133-141. https://doi.org/10.1177/2347631120983481
- Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci 2020;57:365-388. https://doi.org/10.1080/10408363.2020.1783198
- Liu C, von Brunn A, Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov 2020;7:100056.
- Ulrich H, Pillat MM. CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep 2020;16:434-440. https://doi.org/10.1007/s12015-020-09976-7
- Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther 2020;5:283.
- Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Trans Target Ther 2020;5:283.
- Geng J, Chen L, Yuan Y, Wang K, Wang Y, Qin C, et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduct Target Ther 2021;6:347.
- Guindolet D, Gabison EE. Role of CD147 (EMMPRIN/Basigin) in tissue remodeling. Anat Rec (Hoboken) 2020;303:1584-1589. https://doi.org/10.1002/ar.24089
- Bian H, Zheng ZH, Wei D, Zhang Z, Kang WZ, Hao CQ, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. Preprint at: https://doi.org/10.1101/2020.03.21.20040691 (2020).
- Khedkar SA, Malde AK, Coutinho EC, Srivastava S. Pharmacophore modeling in drug discovery and development: an overview. Med Chem 2007;3:187-197. https://doi.org/10.2174/157340607780059521
- Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 2010;15:444-450. https://doi.org/10.1016/j.drudis.2010.03.013
- Kutlushina A, Khakimova A, Madzhidov T, Polishchuk P. Ligand-based pharmacophore modeling using novel 3D pharmacophore signatures. Molecules 2018;23:3094.
- Zhou Y, Tang S, Chen T, Niu MM. Structure-based pharmacophore modeling, virtual screening, molecular docking and biological evaluation for identification of potential poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Molecules 2019;24:4258.
- Torres PH, Sodero AC, Jofily P, Silva-Jr FP. Key Topics in molecular docking for drug design. Int J Mol Sci 2019;20:4574.
- Fan J, Fu A, Zhang L. Progress in molecular docking. Quant Biol 2019;7:83-89. https://doi.org/10.1007/s40484-019-0172-y
- Santos LH, Ferreira RS, Caffarena ER. Integrating molecular docking and molecular dynamics simulations. (Azevedo WF, ed.). In: Docking Screens for Drug Discovery New York: Springer New York, 2019. pp. 13-34.
- PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021;397:1063-1074. https://doi.org/10.1016/S0140-6736(21)00461-X
- Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work. Nat Med 2020 May 15 [Epub]. https://doi.rog/10.1038/d41591-020-00019-9.
- Firth A, Prathapan P. Azithromycin: the first broad-spectrum therapeutic. Eur J Med Chem 2020;207:112739.
- Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: an overview. Eur J Pharmacol 2020;889:173644.
- Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J 2020;96:550-555. https://doi.org/10.1136/postgradmedj-2020-137785
- Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: an old drug with new relevance. Cleve Clin J Med 2018;85:459-467. https://doi.org/10.3949/ccjm.85a.17034
- Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020;177:104762.
- Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020;57:279-283. https://doi.org/10.1016/j.jcrc.2020.03.005
- Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020;92:556-563. https://doi.org/10.1002/jmv.25729
- Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, Ferreira AC, Mattos M, et al. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production. Antimicrob Agents Chemother 2020;64:e00825-20.
- Zhuravel SV, Khmelnitskiy OK, Burlaka OO, Gritsan AI, Goloshchekin BM, Kim S, et al. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine 2021;41:101169.
- Uno Y. Camostat mesilate therapy for COVID-19. Intern Emerg Med 2020;15:1577-1578. https://doi.org/10.1007/s11739-020-02345-9
- Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut 2020;69:1592-1597. https://doi.org/10.1136/gutjnl-2020-321852
- Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem 2020;27:4536-4541. https://doi.org/10.2174/0929867327666200416131117
- Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. Effect of arbidol (umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis 2020;20:954.
- Lokhande AS, Devarajan PV. A review on possible mechanistic insights of nitazoxanide for repurposing in COVID-19. Eur J Pharmacol 2021;891:173748.
- Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis 2021;8:ofab050.
- Wu G, Robertson DH, Brooks CL, Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 2003;24:1549-1562. https://doi.org/10.1002/jcc.10306